CHARM Guidelines for the diagnosis and
|
|
- Maria Howard
- 5 years ago
- Views:
Transcription
1 \ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine, City and Hackney CCG Checked by: Dr Meena Krishnamurthy, GP Respiratory Lead, City and Hackney Dr Angshu Bhowmik, Consultant Respiratory Medicine, HUHFT Debbie Roots, Cardiorespiratory Nurse Consultant HUHFT. Approved by: Homerton Hospital and City and Hackney CCG Joint Prescribing Group. Date: 12 th February Review: 12 th February 2019 Version: 5.2
2 DIAGNOSING COPD Definition of COPD COPD is characterised by airflow obstruction. The airflow obstruction is usually progressive, not fully reversible and does not change markedly over several months. The disease is predominantly caused by smoking. Think of a diagnosis of COPD for patients who are: Over 35 Smokers or ex-smokers Have any of these symptoms o exertion breathlessness o chronic cough o regular sputum production o frequent winter bronchitis or chest infections o wheeze And have no clinical features of asthma (see table below & CHARM asthma guidelines) Perform spirometry if COPD seems likely CXR & FBC at diagnosis Airflow obstruction is defined as: FEV 1<80% predicted or >80% with symptoms And FEV 1/FVC< 70 Consider asthma if >12% FEV 1 reversibility with bronchodilator or corticosteroids. If still doubt about diagnosis consider the following pointers: Clinically significant COPD is not present if FEV 1 and FEV 1/FVC ratio return to normal with drug therapy. Asthma may be present if: o there is a >400ml response to bronchodilators & also >12% reversibility o serial peak flow measurements show significant diurnal or day-to-day variability o there is a >400ml response to 30mg prednisolone daily for 2 weeks Refer for more detailed investigations if needed If still in doubt, consider other possible diagnosis and/or refer for further advice If confirmed COPD: Classify COPD and then start treatment (see flowchart) Severity - Post bronchodilator FEV1/FVC FEV1% Stage < 0.7 > 80% Mild < % Moderate < % Severe < 0.7 <30% Very Severe Reassess diagnosis in view of response to treatment Clinical features differentiating COPD and asthma COPD Asthma Smoker or ex-smoker Nearly all Possibly Symptoms under age 35 Rare Common Chronic productive cough Common Uncommon Breathlessness Persistent and progressive Variable Night-time waking with breathlessness and/or wheeze Uncommon Common Significant diurnal or day-to-day variability of symptoms Uncommon Common For CXR and FBC at ANY time if blood in sputum / weight loss / change in cough
3 Aim of treatment Reduce symptoms: - Relieve symptoms - Improve exercise tolerance - Improve health status Reduce Risk: - Prevent disease progression - Prevent and treat exacerbations - Reduce mortality Treatment 1. Smoking cessation Smoking cessation has the greatest capacity to influence the natural history of COPD. If effective resources and time are dedicated to smoking cessation, long term quit success rates of up to 25% can be achieved. Refer to stop smoking clinics as listed below or a community pharmacy stop smoking service. 2. Vaccinations All patients should be offered the annual flu vaccination and the pneumococcal vaccination once in their lifetime, unless otherwise instructed. 3. Right medication, right inhaler
4 The Right Medication, the Right Inhaler If first line recommendation is NOT suitable (for reasons such as lack of dexterity, side effects etc) which device would be most suitable for my patient? Does my patient have enough inspiratory effort/volume to inhale the contents of a dry powder inhaler? Optimal Inspiratory flow rate L/Min None required** High inspiratory effort required Least inspiratory effort required Device MDI/Respimat Zonda/ Handihaler Turbohaler Spiromax Genuair Accuhaler Ellipta Breezhaler NO Consider a soft mist inhaler or a metered dose inhaler with a spacer. LAMA: Spiriva (Tiotropium) Respimat LAMA/LABA: Spiolto (Tiotropium/Olodaterol) Respimat LABA/ICS: Fostair (Beclometasone/Formoterol) MDI YES Prefers twice daily administration? Consider Turbohaler/Spiromax/Accuhaler/Genuair* LAMA: Eklira Aclidinium Genuair* LAMA/LABA: Duaklir (Aclidinium/Formoterol) Genuair* ICS/LABA: Check inspiratory effort/try placebos to find best device for patient - Fostair (Beclometasone/Formoterol) Nexthaler 100/6 - Seretide Fluticasone/Salmeterol 500/50 Accuhaler - Budesonide/Formoterol 200/6 1-2p BD or Budesonide/Formoterol 400/12 1p BD (Spiromax or Turbohaler) Prefers once daily administration? Consider Ellipta LAMA: Incruse (Umeclidinium) Ellipta LAMA/LABA: Anoro (Umeclidinium/Vilanterol) Ellipta LABA/ICS: Relvar (Vilanterol/Fluticasone) Ellipta *This should also be product of choice to optimise bronchodilation over a 24 hour period. Duration of action of once daily preparations varies from hours. ** MDI with/out spacer and the Respimat device do not require inspiratory effort but does require co-ordination to ensure sufficient inhalation of dose. The Respimat device cannot be used with a spacer. Try placebos or use an in-check dial if available before initiating inhalers. Check inhaler technique at every opportunity. Also see inhaler standards and competency document to aid assessment and
5 Exacerbating patients >2 per year, or 1 leading to hospital admission MRC 1-2 CAT < 10 (FEV1<50%) Management of stable COPD (Based on NICE 2010 clinical guideline and GOLD 2017) All prescribing options to allow prescribing of most appropriate device. Long Acting Beta Agonist+ QUALITY ASSURED SPIROMETRY Post bronchodilator FEV1 1/FVC and FEV 1 %predicted (Classify COPD severity) Exacerbating patient, consider LAMA (as below) as first line, ICS/LABA (or for those with co-morbidity with Asthma) or Ultibro# (LABA/LAMA for COPD patients only if ICS not tolerated or declined. ICS+LABA Inhaled Corticosteroid + Long Acting Beta Agonist If able to use DPI: 1 st : Fostair Nexthaler DPI 100/6 mcg 2 doses BD If requires MDI + spacer 2 nd : Fostair MDI 100/6 mcg 2 doses BD OR depending on patient device preference: Relvar Ellipta DPI 92/22 mcg 1 dose OD OR Duoresp Spiromax DPI 160/4.5 mcg 2 doses BD OR Symbicort Turbohaler DPI 200/6 mcg 2 doses BD OR Seretide 500 Accuhaler DPI 500/50 mcg 1 dose BD Exacerbating and breathless patient, consider ICS/LABA/LAMA ICS+LABA+ LAMA Inhaled Corticosteroid + Long Acting Beta Agonist+ Long Acting Muscarinic Antagonist If able to use DPI: Trelogy Ellipta DPI 92/55/22 1p OD If requires MDI + Spacer: Trimbow MDI 87/5/9 2p BD Patient may also be initiated on a macrolide and/or Roflumilast specialist initiation only Exacerbating patients >2 per year, or 1 leading to hospital admission MRC >3 CAT > 10 (FEV1< 50%) Breathless patients 0-1 exacerbations per year MRC 1-2 CAT < 10 (FEV1>50%) SABA or SAMA Long Acting Beta Agonist or Short Acting Muscarinic Antagonist Salbutamol 100 MDI or 200 Accuhaler, or Bricanyl 500 PRN Or Atrovent 20mcg PRN If continues to be breathless, initiate LAMA or LABA. LAMA Long Acting Muscarinic Antagonist If LAMA started stop the SAMA 1 St : SeeBri Breezhaler DPI 44mcg 1 dose OD OR depending on patient device preference: OR: Braltus Zonda DPI 10mcg 1 dose OD, Incruse Ellipta DPI 55mcg 1 dose OD Eklira Genuair DPI 400mcg 1 dose BD, Spiriva Respimat*Soft Mist 2.5mcg 2 doses OD OR LABA Long Acting Beta Agonist Patients who continue to be breathless despite being on a LAMA or LABA consider dual bronchodilator LAMA+LABA Long Acting Muscarinic Antagonist+ Long Acting Beta Agonist 1 st Ultibro Breezhaler DPI 85/43 mcg 1 dose OD OR depending on patient device preference: Anoro Ellipta DPI 55/22mcg 1 dose OD OR Duaklir Genuair DPI 400/12mcg 1 dose BD OR Spiolto Respimat Soft Mist 2.5/2.5mcg 2 doses OD Breathless patients 0-1 exacerbations MRC >3 CAT >10 (FEV1>50%) 1 st : Onbrez Breezhaler DPI mcgs 1 dose OD OR Serevent 25mcg 2 doses BD (MDI or Accuhaler), Oxis Turbohaler DPI 12mcg 1 dose BD # Ultibro is currently the only LABA/LAMA that shows evidence of reducing exacerbations when compared to ICS/LABA. *Salbutamol may continue at all stages, SAMA discontinued if LAMA initiated. ** Second line agents to be used in patients who have not tolerated 1st line agents and should be based on device most appropriate for the patient. Consider de-escalation where appropriate. For those with a chronic productive cough, consider trial of mucolytic therapy. Consider referral for long term oxygen therapy if Spo2 <92% on room air and stable MRC: Medical Research Council dyspnoea scale Please refer to the right medication, the right inhaler for more information. For all patients ensure the following: - Inhaler technique and adherence checked at every opportunity - Smoking cessation for all smokers - Flu and Pneumococcal pneumonia vaccinations - Self-management and rescue medication are in place where appropriate - Pulmonary rehabilitation offered to all patients with MRC 3 or MRC =2 with symptoms. - Advice on exercise and nutrition -Consider advance care planning and referral to Breathing Space Clinic in more advanced COPD Written by: Hetal Dhruve (Specialist Respiratory Pharmacist) City and Hackney CCG Checked by: Dr Angshu Bhowmik, Consultant Respiratory Medicine, HUHFT, Debbie Roots, Cardiorespiratory Nurse Consultant, HUHFT, Dr Meena Krishnamurthy, GP Respiratory Lead, City and Hackney CCG Approved by: JPB. Date of approval: 12/02/18, Date of revision: 12/02/19 Version: 5.2
6 The right medication, the right inhaler. Consider your patient: Select device most appropriate for your patient. - What inhalers are they using? - How is the inhaler technique poor/moderate/good. - Does the patient have a history of asthma? - ICS must not be stopped if there is any history of Asthma regardless of severity of COPD Prescribing options Component(s) Brand Dose Device Key inhaler technique* LABA LONG ACTING BETA AGONIST Price/30 days Indacaterol Onbrez mg 1p OD Breezhaler Long and deep Salmeterol Serevent 25mcg 2p BD Available as accuhaler/mdi Accuhaler: Long and deep MDI: Slow and steady LAMA LONG ACTING MUSCARINIC ANTAGONIST Formoterol Oxis 12mcg 1p BD Turbohaler Long and deep Glycopyrronium Seebri 44mcg 1p OD Breezhaler Long and deep Tiotropium Braltus 10mcg 1p OD Zonda Long and deep Aclidinium Eklira 400mcg 1p BD Genuair Long and deep Umeclidinium Incruse 55mcg 1p OD Ellipta Long and deep Tiotropium Spiriva 2.5mcg 2p OD Respimat Slow and steady LABA+LAMA LONG ACTING BETA AGONIST + LONG ACTING MUSCARINIC ANTAGONIST Glycopyrronium + Indacaterol Ultibro 85/43 1p OD Breezhaler Long and deep Umeclidinium + Vilanterol Anoro 55/22 mcg 1p OD Ellipta Long and deep Aclidinium+ Formoterol Duaklir 340/12mcg 1p BD Genuair Long and deep Tiotropium + Olodaterol Spiolto 2.5/2.5mcg 2p OD Respimat Slow and steady ICS/LABA INHALED CORTICOSTEROIDS + LONG ACTING BETA AGONIST Beclomethasone + Formoterol Fostair 100/6 2p BD MDI Slow and steady Beclomethasone + Formoterol Fostair 100/6 2p BD Nexthaler Long and deep Fluticasone + Vilanterol Relvar 92/22 1p OD Ellipta Long and deep Fluticasone + Salmeterol Seretide 500/50 1p BD Accuhaler Long and deep Budesonide + Formoterol Symbicort 200/6 2p BD Turbohaler Long and deep 28 Budesonide + Formoterol Duoresp 160/4.5 2p BD Spiromax Long and deep Beclomethasone+ Formoterol + Glycopyrronium Fluticasone + Vilanterol + Umeclidinium ICS+LABA+LAMA Trimbow 87/5/9 2p BD MDI Slow and steady Trelegy 92/22/55 1p OD Ellipta Long and deep **NOTE Seretide 250 evohaler, Sirdupla 250/25 and Sereflo 250/25 are NOT licensed for use in COPD but may be continued for patients who are already established on treatment and have no history of pneumonia. If a patient is unable to use the long acting muscarinic antagonist, an ipratropium inhaler (SAMA) with spacer may be considered. This would be off-license use. ** Please refer to patient information leaflets/spc s or for full instruction on inhaler technique. # Prices correct at time of update: 12/02/18. Reference MIMS online.
7 Quality of Life CAT (COPD ASSESSMENT TEST) SCORE I never cough I cough all the time I have no phlegm (mucus) in my chest at all My chest is full of phlegm (mucus) My chest does not feel tight at all My chest feels very tight When I walk up a hill or one flight of stairs I am not When I walk up a hill or one flight of stairs I Breathless am very breathless I am not limited doing any activities at home I am very limited doing activities at home I am confident leaving my home despite my lung Condition I am not at all confident leaving my home because of my lung condition I sleep soundly I don t seem soundly because of my lung Condition I have lots of energy I have no energy at all MRC (MEDICAL RESEARCH COUNCIL) DYSPNOEA SCALE Grade Degree of breathlessness related to activities 1 Not troubled by breathlessness except on strenuous exercise 2 Short of breath when hurrying on the level or walking up a slight hill 3 Walks slower than most people on the level, stops after a mile or so, or stops after 15 minutes walking at own pace. 4 Stops for breath after walking about 100 yards or after a few minutes on level ground 5 Too breathless to leave the house, or breathless when undressing OTHER PHARMACOTHERAPY Oral theophyllines can be considered but they have a high-risk side effect profile and interact with many other medication and cigarette smoke. Theophylline levels should therefore be monitored as per MHRA guidelines to prevent toxicity. Chronic cough productive of viscous sputum - consider 4 week trial of mucolytic agent e.g carbocisteine 750mg 3 times a day initially then 2 times a day; reassess benefit after 4 weeks. Patients who frequently exacerbate may be initiated on macrolide prophylaxis by specialist only.
8 PULMONARY REHABILITATION (PR) PR is gold standard symptom based treatment of exercise and education, aimed at promoting long term behaviour change and compliance with health enhancing behaviours. A referral to outpatient PR should be considered for all COPD patients with MRC grade 3-5 or MRC 2 with breathlessness on exertion as per NICE guidance. Post exacerbation PR should be considered for all patients admitted with an acute exacerbation of COPD within 4 weeks of discharge from hospital. To refer to the ACERs Pulmonary Rehabilitation Service HomertonCOPD@nhs.net or call for a referral form. OXYGEN ASSESSMENT Refer to ACERS Oxygen Assessment Service, Respiratory Department, Homerton Hospital for long term and ambulatory oxygen assessment if oxygen saturations <92% on air, severe COPD, peripheral oedema. All patients who receive LTOT should be assessed annually with Blood gas analysis inform ACERS on to undertake this assessment DEPRESSION & ANXIETY There is a high prevalence (30-50%) of depression seen in COPD patients with frequent exacerbations. NICE guidelines recommend a high index of suspicion and prompt diagnosis. Treat anxiety and depression with medication, taking time to explain to the patient why this is needed and refer to psychology services if needed END OF LIFE CARE Opiates should be used when appropriate to palliate breathlessness in patients with end stage COPD which is unresponsive to other medical therapy. Patients with end stage COPD and their families should have access to the full range of services offered by the multidisciplinary palliative care teams, including admission to hospices. Prognosis in COPD is difficult, but recognized indicators of a poor outcome are: Hospital admissions Severe disease On long term oxygen therapy Depression, poor quality of life, housebound Co-morbidity, especially heart failure Low BMI Consider asking would I be surprised if my patient were to die in the next twelve months? Consider inclusion on supportive and palliative care register Refer to ACERS for onward referral to the Breathing Space clinic at St Joseph s Hospice ACUTE INFECTIVE EXACERBATION OF COPD : ALL EXACERABTIONS REF TO ACERS TEAM Antibiotics are usually ONLY given if there is a history of increased sputum purulence: 1 st line PO Doxycycline 200mg stat then 100mg once a day for 4 days or PO Clarithromycin 500mg twice a day/po Amoxicillin 500mg three times a day for 5 days if doxycycline contraindicated AND oral steroids Prednisolone 30mg daily for 7 days. Gradual withdrawal of Prednisolone - Should be considered for the following patients - Received more than 40mg of prednisolone daily for more than 1 week - Been given repeat doses in the evening, - Recently received repeated courses (particularly if taken for longer than 3 weeks), - Taken a short course within 1 year of stopping long-term therapy Increase frequency of salbutamol 2 puffs every 4 hours, use spacer - PROTOCOL FOR THE TREATMENT & PREVENTION OF EXACERBATIONS IN COPD
9 IS IT AN EXACERBATION? Key features typically associated with exacerbation are 2 or more of the following. Worsening breathlessness Increased sputum volume Increased cough Fever Chest tightness Changing sputum colour Wheeze If yes to any If no to all FACTORS PROMPTING CONSIDERATION OF HOME MANAGEMENT VS. HOSPITAL ADMISSION Coping at home Normal level of consciousness Experiencing only mild breathlessness maintaining usual level of activity Eating & drinking normally Little change to usual general condition Easy access to help if required Lack of significant co morbidity If yes to most If no to most MANAGE PATIENT AT HOME & REFER TO ACERS DISCUSS WITH ACERS / ADMIT PATIENT TO HOSPITAL IN EMERGENCY MANAGE ACUTE EXACERBATION Add or increase bronchodilator use Review inhaler technique Prescribe antibiotics if sputum becomes purulent Consider oral corticosteroids Pulse oximetry if severe exacerbation Increase social support if necessary AGREE TO FOLLOW UP & REVIEW PATIENT TO ASSESS THEIR COPD POST EXACERBATION MANAGEMENT PLAN Patient understands personal self management plan, rescue medication should be supplied for future use for patients who have had an exacerbation or at risk of one (where appropriate) as above. Ensure adherence and inhaler technique is optimised.
Wirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationCOPD Prescribing Guidelines
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationCHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationMedicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationChronic Obstructive Pulmonary Disease (COPD) Primary Care Guideline
Chronic Obstructive Pulmonary Disease (COPD) Primary Care Guideline For use across all Norfolk & Waveney CCGs Based on GOLD 2017 1, NICE CG101 COPD 2. Norfolk & Waveney Group In the UK in 2012, 29,776
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationChronic Obstructive Pulmonary Disease (COPD) Management
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Chronic Obstructive Pulmonary Disease (COPD) Management Diagnosis of COPD should be considered in patients over the age of 35 who have a risk factor (generally
More informationNHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group
NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group Inhaler technique and respiratory conditions Guidance Sheet 16 When diagnosed
More informationDose. Route. Units. Given. Dose. Route. Units. Given
Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening
More informationASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12
North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationGMMMG COPD Formulary Inhaler Options October 2017
BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationCOPD Patient Care Pathway
COPD Patient Care Pathway Northumberland Clinical Commissioning Group North Tyneside Clinical Commissioning Group Contents The Pathway 1. Identification and Diagnosis.......................P3 2. Annual
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationEvidence Review for Prescribing Clinical Network
Summary page Evidence Review for Prescribing Clinical Network Treatment: LABA/LAMA Combination devices in COPD Anoro Ellipta, Ultibro and Duaklir Genuair Prepared by: Noreen Devanney Topic Submitted by:
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationReport generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section.
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACLIDINIUM BROMIDE bronchodilators ADRENALINE/EPINEPHRINE
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More information3. Respiratory System
1 3. Respiratory System Also see Appendix 3A Guidance on Management of Also see Appendix 3B Preferred Inhaler Devices for Adults Also see Appendix 3C Preferred Inhaler Devices for Adolescents (12-18 years)
More informationChronic Obstructive Pulmonary Disease (COPD)
NHS Eastern Cheshire Clinical Commissioning Group NHS South Cheshire Clinical Commissioning Group NHS Vale Royal Clinical Commissioning Group Mid Cheshire Hospitals NHS Foundation Trust East Cheshire NHS
More informationRespiratory Inhaler Check-up Service
Respiratory Inhaler Check-up Service Dr Toby Capstick Lead Respiratory Pharmacist Leeds Teaching Hospitals NHS Trust toby.capstick@nhs.net 8 th May 2018 What is the Challenge? The Burden of Disease in
More informationOutline. EPIC Project. February EPIC Project. Diagnosis: Spirometry. Differentiation between COPD & Asthma
EPIC Project Enabling Patient health Improvements though COPD medicines optimisation Dr Toby Capstick Toby.capstick@nhs.net Outline Background on COPD COPD Assessment Cost Effective Treatment Medication
More informationInclude patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma
More informationWhat is the Challenge?
Respiratory Inhaler Check-up Service What is the Challenge? Dr Toby Capstick Lead Respiratory Pharmacist Leeds Teaching Hospitals NHS Trust toby.capstick@nhs.net 25 th September 2018 The Burden of Disease
More informationAdult Summary flowchart for Asthma Switch and Step Down to preferred inhaler choices
HVCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to preferred
More informationAdult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices
ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationStepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs
Step Down guidance Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs Important Complete asthma control needs to be achieved for at least 12 weeks before attempting to step patients
More informationPosition within the Organisation
ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September
More informationThese lung function tests involve you being seated and breathing into specialist equipment (like that shown below), via a filter and a mouthpiece.
Lung Function Tests This leaflet only gives you general information about the lung function (breathing) tests. However, it does not replace the need for the personal advice from the health care professional.
More informationCommunity COPD Service Protocol
Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults
More informationWhy should I read this booklet?
COPD The basics Why should I read this booklet? This booklet contains information for people who have recently been told by their doctor that they have a condition called Chronic Obstructive Pulmonary
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationChronic Obstructive Pulmonary Disease (COPD) Guideline
Chronic Obstructive Pulmonary Disease (COPD) Guideline Unique ID: NHSL Author (s): Professor William MacNee, Dr. Gourab Choudhury. Lothian Respiratory (COPD) MCN Category/Level/Type: Level 2 Guideline
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE Bulletin 218: September 2015 Review Date: September 2018 LAMA / LABA combination inhalers in COPD- Place in therapy review and choice of therapy JPC Recommendations:
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationMedicines Management of Chronic Obstructive Pulmonary Disorder (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disorder (COPD) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (NHS Wandsworth) and Reena Rabheru-Dodhy (NHS Sutton & Merton) Date Prepared:
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
A F O C A l p O I N T l E A r N I N g p r O g r A m m E CHRONIC OBSTRUCTIVE PULMONARY DISEASE S E C O N D E D I T I O N BOOK 2 September 2013 FP120/2 CENTRE FOR PHARMACY POSTGRADUATE EDUCATION focal point
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationChapter 3: Respiratory System (7 th Edition)
Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment
More informationCOPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations
More informationA multitude of devices
A multitude of devices Dr Andrew Scroop Respiratory Consultants 15 th September 2018 STEPWISE PHARMACOLOGICAL MANAGEMENT OF STABLE COPD COPD Inhalers MILD FEV 1 60 80% predicted few symptoms breathless
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More informationCOPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy
Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic
More informationApril 10 th, Bond Street, Toronto ON, M5B 1W8
Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond
More informationSelf-management plan for COPD
Sheffield Clinical Commissioning Group Sheffield Teaching Hospitals NHS Foundation Trust Self-management plan for COPD This is your personal management plan The aim of the plan is to help you have better
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationWhat is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018
What is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018 No disclosures Disclosures objectives How to diagnose & Assess severity Treatment: Pharmacologic Non-Pharmacologic Maintenance
More informationCOPD RESOURCE PACK Section 5. Drug Treatment & Inhalers in Stable COPD
COPD RESOURCE PACK Section 5 Drug Treatment & Inhalers in Stable COPD In this section: 1. Links to Fife Formulary 2. Pharmacological Management of Stable COPD 3. How to use a Metered Dose Inhaler 4. How
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review date: December 2017 Bulletin 208 : Indacaterol + Glycopyrronium bromide 85/43 micrograms (Ultibro Breezhaler ) for the Treatment
More informationSummary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationCOPD-X. Concise Guide for Primary Care
www.copdx.org.au This Guide aims to provide evidence-based practical recommendations for healthcare professionals on the diagnosis and management of chronic obstructive pulmonary disease (COPD). COPD-X
More informationPATIENT INFORMATION Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet
PATIENT INFORMATION Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet What is COPD? COPD is a general term, which includes the conditions chronic asthma, chronic bronchitis and emphysema. It is due
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationHe is still Short of Breath Is there any new puffer? Saidul Ansary
He is still Short of Breath Is there any new puffer? Saidul Ansary Mr S C 66 yr. old retired Engineer for pre op elective assessment I am fine but Anaesthetist said I need to see you. I am little bit SOB,
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2015 Review Date: September 2018 Bulletin 219: Choice of Long Acting Muscarinic Agent (LAMA) inhaler for COPD JPC Recommendation: The availability
More informationProgress, Paediatrics and Protocols. Dr Andy Powell Dr Lesley Ayling West Hampshire CCG
Progress, Paediatrics and Protocols Dr Andy Powell Dr Lesley Ayling West Hampshire CCG Progress Solutions CQUIN discharge bundle (including personal action plan), specialist review, immediate management
More informationbeclometasone 100 MDI 2 puffs twice a day (recently changed to non CFC (Clenil Modulite))
Case 1 Mr Thomson, a 32 year old asthmatic who is well known to you comes into your pharmacy. He is known to have a best peak flow of 640 L/min. He tells you that over the last few weeks he has been wakening
More informationRESPIRATORY INHALERS
RESPIRATORY INHALERS The correct administration of inhaled therapy is essential for successful, cost-effective and safe therapy. Everyone, including the patient needs to understand the importance of ensuring
More informationWhy Asthma Still Kills The National Review of Asthma Deaths (NRAD)
APPROVED FINAL VERSION NHS Protect Why Asthma Still Kills The National Review of Asthma Deaths (NRAD) Summary of Recommendations for GP Practices and Community Pharmacies Author: Anne Henry Contact: anne.henry@nhs.net
More informationCOPD 2016 What to do with all these New Inhalers?
COPD 2016 What to do with all these New Inhalers? Planning committee Content Experts Clinical reviewers Paul Hernandez MDCM FRCPC, Department of Respirology, QEII Health Sciences Centre, Associate Professor,
More informationASTHMA. Dr Liz Gamble BRI
ASTHMA Dr Liz Gamble BRI Diagnosis Clinical: wheeze, breathlessness, chest tightness, cough Variable airflow obstruction: peak flow chart, spirometry with reversibility to bronchodilators Airways hyper-responsiveness
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More information